Acyclovir in pityriasis rosea: An observer-blind, randomized controlled trial of effectiveness, safety and tolerability
Background: Pityriasis rosea (PR) is an acute inflammatory dermatosis. The association of human herpes virus 6 and 7 suggests the utility of use of antiviral agents in this disease. Aims and Objectives: To evaluate the effectiveness and safety of acyclovir in the treatment of PR. Methods: An observe...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2015-01-01
|
| Series: | Indian Dermatology Online Journal |
| Subjects: | |
| Online Access: | http://www.idoj.in/article.asp?issn=2229-5178;year=2015;volume=6;issue=3;spage=181;epage=184;aulast=Das |
| _version_ | 1818179626775609344 |
|---|---|
| author | Anupam Das Amrita Sil Nilay Kanti Das Kunal Roy Amal Kanti Das Debabrata Bandyopadhyay |
| author_facet | Anupam Das Amrita Sil Nilay Kanti Das Kunal Roy Amal Kanti Das Debabrata Bandyopadhyay |
| author_sort | Anupam Das |
| collection | DOAJ |
| description | Background: Pityriasis rosea (PR) is an acute inflammatory dermatosis. The association of human herpes virus 6 and 7 suggests the utility of use of antiviral agents in this disease. Aims and Objectives: To evaluate the effectiveness and safety of acyclovir in the treatment of PR. Methods: An observer-blind, randomized (1:1), parallel group, add-on trial was conducted on 24 adult patients with PR. Subjects of both Group A and B received the standard of care in the form of cetirizine 10 mg OD and calamine. Group A in addition received acyclovir 400 mg tablets thrice daily for 7 days. Both groups were followed up for four consecutive weeks for assessment of effectiveness and adverse events. Results: Group A complained of significantly fewer new lesions than Group B (P = 0.046). A complete response was obtained in all patients of Group A and 83% patients of Group B at the end of the follow up period. There was significant reduction in both lesional score and pruritus at second week follow-up in Group A and third week follow-up in Group B (P < 0.05). Minor adverse effects were observed in both treatment arms. Conclusion: Acyclovir offered rapid resolution of clinical severity of PR from second week onwards without significantly increased adverse events as compared to supportive therapy alone. |
| first_indexed | 2024-12-11T21:06:52Z |
| format | Article |
| id | doaj.art-8244d3eeabdf461ea60dfe870d7ddd11 |
| institution | Directory Open Access Journal |
| issn | 2229-5178 |
| language | English |
| last_indexed | 2024-12-11T21:06:52Z |
| publishDate | 2015-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Indian Dermatology Online Journal |
| spelling | doaj.art-8244d3eeabdf461ea60dfe870d7ddd112022-12-22T00:50:50ZengWolters Kluwer Medknow PublicationsIndian Dermatology Online Journal2229-51782015-01-016318118410.4103/2229-5178.156389Acyclovir in pityriasis rosea: An observer-blind, randomized controlled trial of effectiveness, safety and tolerabilityAnupam DasAmrita SilNilay Kanti DasKunal RoyAmal Kanti DasDebabrata BandyopadhyayBackground: Pityriasis rosea (PR) is an acute inflammatory dermatosis. The association of human herpes virus 6 and 7 suggests the utility of use of antiviral agents in this disease. Aims and Objectives: To evaluate the effectiveness and safety of acyclovir in the treatment of PR. Methods: An observer-blind, randomized (1:1), parallel group, add-on trial was conducted on 24 adult patients with PR. Subjects of both Group A and B received the standard of care in the form of cetirizine 10 mg OD and calamine. Group A in addition received acyclovir 400 mg tablets thrice daily for 7 days. Both groups were followed up for four consecutive weeks for assessment of effectiveness and adverse events. Results: Group A complained of significantly fewer new lesions than Group B (P = 0.046). A complete response was obtained in all patients of Group A and 83% patients of Group B at the end of the follow up period. There was significant reduction in both lesional score and pruritus at second week follow-up in Group A and third week follow-up in Group B (P < 0.05). Minor adverse effects were observed in both treatment arms. Conclusion: Acyclovir offered rapid resolution of clinical severity of PR from second week onwards without significantly increased adverse events as compared to supportive therapy alone.http://www.idoj.in/article.asp?issn=2229-5178;year=2015;volume=6;issue=3;spage=181;epage=184;aulast=DasAcyclovircetirizinepityriasis rosea |
| spellingShingle | Anupam Das Amrita Sil Nilay Kanti Das Kunal Roy Amal Kanti Das Debabrata Bandyopadhyay Acyclovir in pityriasis rosea: An observer-blind, randomized controlled trial of effectiveness, safety and tolerability Indian Dermatology Online Journal Acyclovir cetirizine pityriasis rosea |
| title | Acyclovir in pityriasis rosea: An observer-blind, randomized controlled trial of effectiveness, safety and tolerability |
| title_full | Acyclovir in pityriasis rosea: An observer-blind, randomized controlled trial of effectiveness, safety and tolerability |
| title_fullStr | Acyclovir in pityriasis rosea: An observer-blind, randomized controlled trial of effectiveness, safety and tolerability |
| title_full_unstemmed | Acyclovir in pityriasis rosea: An observer-blind, randomized controlled trial of effectiveness, safety and tolerability |
| title_short | Acyclovir in pityriasis rosea: An observer-blind, randomized controlled trial of effectiveness, safety and tolerability |
| title_sort | acyclovir in pityriasis rosea an observer blind randomized controlled trial of effectiveness safety and tolerability |
| topic | Acyclovir cetirizine pityriasis rosea |
| url | http://www.idoj.in/article.asp?issn=2229-5178;year=2015;volume=6;issue=3;spage=181;epage=184;aulast=Das |
| work_keys_str_mv | AT anupamdas acyclovirinpityriasisroseaanobserverblindrandomizedcontrolledtrialofeffectivenesssafetyandtolerability AT amritasil acyclovirinpityriasisroseaanobserverblindrandomizedcontrolledtrialofeffectivenesssafetyandtolerability AT nilaykantidas acyclovirinpityriasisroseaanobserverblindrandomizedcontrolledtrialofeffectivenesssafetyandtolerability AT kunalroy acyclovirinpityriasisroseaanobserverblindrandomizedcontrolledtrialofeffectivenesssafetyandtolerability AT amalkantidas acyclovirinpityriasisroseaanobserverblindrandomizedcontrolledtrialofeffectivenesssafetyandtolerability AT debabratabandyopadhyay acyclovirinpityriasisroseaanobserverblindrandomizedcontrolledtrialofeffectivenesssafetyandtolerability |